Other languages Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
12.28 ^USD	-4.58%		-28.40%	+80.06%

May. 08	Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 07	Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Y-mAbs Therapeutics, Inc. Announces Resignation of Gérard Ber, Ph.D. from the Board of Directors, Effective June 10, 2024	Apr. 29
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	Mar. 14
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	Mar. 14
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	Mar. 04
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
Y-mAbs Therapeutics to Join NASDAQ Biotechnology Index Dec. 18	Dec. 13
Y-mabs Therapeutics Insider Bought Shares Worth $521,294, According to a Recent SEC Filing	Nov. 29
Y-mabs Therapeutics Insider Sold Shares Worth $795,383, According to a Recent SEC Filing	Nov. 22
Y-mAbs Therapeutics Q3 Net Loss Narrows, Revenue Rises	Nov. 13
Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023	Nov. 13
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Y-mAbs Therapeutics, Inc. Announces Management Changes	23-10-18
Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023	23-10-18
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA	23-10-18
Y-mAbs Therapeutics Gets US FDA Clearance for Investigational New Drug Application for CD38-SADA	23-10-17
Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma	23-10-16
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Other languages

Filters